Linked research, clinical, and regulatory source pathways.
Company profile
About SOPHiA GENETICS
SOPHiA GENETICS is a health technology company that has built SOPHiA DDM™, an AI-powered platform for precision medicine that transforms complex health data into actionable clinical insights. The platform serves healthcare providers, biopharma companies, and patients globally, focusing primarily on oncology and rare genetic disorders. With a network of over 990 healthcare institutions across 75+ countries, SOPHiA GENETICS has analyzed more than 2.5 million genomic profiles. The company's technology combines advanced AI analytics with cloud-based infrastructure to deliver 98-99% accuracy across multiple health data sets. Their platform supports comprehensive genomic analysis including solid tumors, blood cancers, hereditary cancers, liquid biopsy, and rare and inherited disorders. SOPHiA GENETICS offers end-to-end solutions from library preparation through variant interpretation, with applications spanning clinical exomes, whole exomes, and targeted panels. The company emphasizes data sovereignty, ensuring healthcare institutions maintain full control of their data while benefiting from collective intelligence across the global network. Their diverse team from 28 countries includes 30% PhD holders, bringing deep expertise in biology, data science, and clinical genomics. SOPHiA GENETICS is committed to breaking barriers in healthcare access, working to ensure every patient has access to precision care regardless of location or circumstance.
Company description SOPHiA GENETICS official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at SOPHiA GENETICS?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Blood cancers
- Chronic lymphocytic leukemia
- Hereditary cancers
- Inherited disorders
- Kidney cancer
- Myeloproliferative neoplasms
- Ovarian cancer
- Rare disorders
- Solid tumors
Who it serves
- Academic medical centers
- BioPharma companies
- Diagnostic companies
- Health Systems
- Hospital laboratories
- Reference laboratories
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: Element AVITI, MGI DBNSEQ-T7, MSK-ACCESS, MSK-IMPACT, NextSeq 2000, NextSeq 550, NovaSeq 6000, NovaSeq X, OncoKB.
Geographic context
MarketsEurope · Global presence across 75+ countries · Latin America · North America · Panama mentioned specifically
Company sourceOfficial website
Company milestones
Platform expansion
Reached 2 million genomic profiles analyzed milestone; announced Master Collaboration Agreement with ARC Regulatory for IVDR expertise; launched Enhanced Exome Solutions; expanded liquid biopsy capabilities with MSK-ACCESS; partnership with Jessa Ziekenhuis announced at European Congress of Pathology
Partnerships
Recorded partners
- ARC Regulatory
- French Kidney Cancer Research Network (UroCCR)
- Henry Ford Health
- Jessa Ziekenhuis
- Laboratorio Barnafi-Krause
- Memorial Sloan Kettering Cancer Center (MSK)
- Sanatorio Americano
- The Royal Marsden NHS Foundation Trust
- TomaLab Advanced Biomedical Assays
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).Clinical cancer research : an official journal of the American Association for Cancer Research · Jul 22, 2026
Severe trauma and chronic stress: seeds and fruits of epigenetic sensitivity.Genetica · May 14, 2026
Enhanced Detection of BRCA Copy Number Alterations Within a Commercial HRD Assay: Implications for Precision Oncology in Ovarian Cancer.International journal of molecular sciences · Apr 29, 2026
Multimodal imaging to analyze the biomechanical properties of kidney tumors, evaluating feasibility, inter-modality correspondence, and diagnostic value (UroCCR-115).PloS one · Jan 1, 2026
Establishment and molecular profiling of a PDX model of a metachronous brain tumor in a patient with constitutional mismatch repair deficiency with biallelic MSH6 variant.Animal models and experimental medicine · Nov 1, 2025
Extensive folding variability between homologous chromosomes in mammalian cells.Molecular systems biology · Jul 1, 2025
Clinical validation
Clinical-trial records
Analytical Validation of Circulating DNA Analysis Methods: Creation of a Control CohortNCT07663994 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
98-99% accuracy
Platform analyzes multiple health data sets
2.5M+ genomic profiles analyzed
Cumulative platform usage across global network
0.5% VAF sensitivity
Variant detection using CUMIN UMI technology
~20,000x sequencing depth
MSK-ACCESS liquid biopsy solution
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from SOPHiA GENETICS
Recent articles published on SOPHiA GENETICS's official website.
Diversity in Genomic Analysis: An example of how SOPHiA GENETICS has built more accurate health data analysis for diverse populations
Read on SOPHiA GENETICSCelebrating 1 Year of SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution!
Read on SOPHiA GENETICSCelebrating Clinical Trials Day
Read on SOPHiA GENETICSIn the Face of Rare Disease: The Inspiring Story of Brooklynn
Read on SOPHiA GENETICSThe Launch of SOPHiA DDM™ Dispatch
Read on SOPHiA GENETICS07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.